PeptideDeepDive
MOTS-c Peptide: Evidence, Safety & Legal Status
MOTS-c is a mitochondrial-derived peptide studied in energy metabolism, AMPK signalling and exercise biology. Human research mainly measures the body’s own MOTS-c; controlled studies administering MOTS-c as a treatment have not established clinical benefits or long-term safety.
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region. Cell and animal research links it to energy balance and AMPK signalling, while human studies show that endogenous MOTS-c can change with exercise and metabolic state. FDA has not approved MOTS-c and, in its 2026 review, identified no clinical studies administering MOTS-c-related drug substances to people.
Het redactieteam van PeptideDeepDive checks mechanism claims against primary research and legal claims against FDA, MHRA, HPRA and EU sources. Importantly, we separate studies that measure the body’s own MOTS-c from studies that would give MOTS-c as a treatment. We do not list a medical reviewer because we have not verified one. Regulatory wording, internal links, supplier data and the available MOTS-c batch report were rechecked on 21 September 2026. This guide is for education only and does not give dosing, treatment or legal advice.
What Is MOTS-c Peptide?
The mitochondrial 12S rRNA region encodes MOTS-c, a 16-amino-acid peptide. Unlike BPC-157 en TB-500, researchers do not mainly study it for tissue repair. Instead, they study energy balance, muscle signalling, insulin-related biology, stress responses and exercise.
The FDA has not approved MOTS-c for any use. In addition, its 2026 briefing says that no FDA-approved drug contains MOTS-c free base or MOTS-c acetate. The FDA also found no clinical studies that gave these MOTS-c-related substances to people. Meanwhile, MOTS-c does not hold a standard medicine marketing authorisation in the UK or EU.
How MOTS-c Is Thought to Work: AMPK & Mitochondrial Signalling
The original 2015 Cell Metabolism paper described MOTS-c as a mitochondrial signal involved in energy balance. In mouse and cell models, it changed folate and purine metabolism, increased AICAR and activated AMPK, an energy-sensing pathway. Read the original MOTS-c study. Moreover, later work found that exercise increased the body’s own MOTS-c in human muscle and blood. However, those findings do not show that injected MOTS-c treats metabolic disease in people.
What Does MOTS-c Evidence Actually Show?
The human evidence needs one key distinction. Several studies have measured the body’s own MOTS-c in people, including exercise studies and work on blood levels. For example, a 2021 Nature Communications study found that exercise increased MOTS-c in human muscle and circulation. See the human exercise study. However, the FDA’s 2026 review found no clinical studies that gave MOTS-c-related drug substances to people. Therefore, exercise and biomarker studies should not be presented as proof that MOTS-c works as a treatment.
The FDA also found no human exposure or drug-level data for MOTS-c-related bulk substances. As a result, clinical trials have not established a treatment dose, long-term safety or effectiveness for the proposed uses. Accordingly, this article does not provide dosing guidance.
What the available 40mg MOTS-c report actually shows
The supplier-submitted Analiza Białek report for lot 86263 reports chromatographic quantity and purity for a 40mg MOTS-c vial. It does not report microbiology, endotoxin or elemental-impurity testing.
View the report summary and scope limitations. Analytical documentation is not evidence of clinical efficacy, safety or regulatory approval.
MOTS-c FDA Status in 2026: Approval, 503A & Safety Gaps
MOTS-c had no FDA drug approval and no applicable USP/NF drug-substance monograph. The original sponsor later withdrew the nomination. Nevertheless, the FDA chose to review MOTS-c free base and MOTS-c acetate on its own initiative.
The FDA’s Pharmacy Compounding Advisory Committee discussed MOTS-c-related bulk substances for possible inclusion on the 503A Bulks List. For example, the public agenda listed obesity and osteoporosis among the uses under review. However, the FDA said the nomination lacked enough information for several proposed uses and that it found no clinical studies that gave MOTS-c to people.
FDA has not approved MOTS-c for any use. Its 2026 briefing found no applicable USP/NF monograph, no FDA-approved drug containing MOTS-c free base or acetate and no clinical studies administering those substances to people. FDA also highlighted naming, characterisation, peptide-impurity and potential immunogenicity concerns. FDA staff proposed that neither MOTS-c free base nor MOTS-c acetate be added to the 503A Bulks List. Read the FDA MOTS-c briefing document.
FDA’s current compounding-safety page separately states that compounded MOTS-c may pose immunogenicity and peptide-characterisation risks and that the agency has not identified human exposure data for MOTS-c drug products. That is an important distinction from studies measuring naturally occurring MOTS-c in the body.
Is MOTS-c Legal in the UK, Ireland, Germany & EU?
MOTS-c does not hold the standard medicine marketing authorisation that approved medicines have in the UK or EU. However, that does not create one simple Europe-wide rule for every question about possession, import or supply. Instead, each country can apply its own rules on unlicensed medicines and customs. Therefore, the summaries below focus on medicine-authorisation status and do not give legal advice.
🇬🇧 United Kingdom MHRA
MOTS-c is not a UK-licensed medicine. However, MHRA rules allow limited supply of some unlicensed medicines for a specific clinical need. Therefore, readers should not treat “unlicensed” as a blanket answer to every possession or import question.
🇮🇪 Ireland HPRA
The HPRA medicines framework does not list MOTS-c as a standard authorised human medicine. However, authorisation status does not answer every import or supply question. So, a real-world case should be checked against current HPRA guidance.
🇩🇪 Germany EU / National Rules
MOTS-c has no standard EU marketing authorisation as a medicine. Germany also applies national rules to manufacture, supply and import. Therefore, the lack of authorisation should not be reduced to one universal “legal/illegal” label.
🇪🇺 European Union Directive 2001/83/EC
EU medicines law generally requires marketing authorisation before a company places a medicinal product on a member-state market, subject to national exceptions. MOTS-c does not hold a standard EU medicine authorisation for the uses covered in this guide.
For the EU framework, Article 6 of Directive 2001/83/EC sets the general marketing-authorisation rule. Read Directive 2001/83/EC. For UK rules, see the MHRA guidance on unlicensed medicines. In addition, Irish readers can use the HPRA medicines search.
MOTS-c vs BPC-157 & TB-500: How They Compare
| Peptide | Primary research focus | Human evidence | 2026 regulatory note |
|---|---|---|---|
| MOTS-c | Mitochondrial / metabolic signalling | Human endogenous biomarker and exercise data; no administered-human clinical studies identified by FDA | FDA staff proposed not adding MOTS-c free base or acetate to 503A list; no drug approval |
| BPC-157 | Soft-tissue and gut research | Extremely limited human evidence | Separate FDA 503A/PCAC review; no drug approval |
| TB-500 | Wound / soft-tissue research | Limited and molecule-specific human context | Separate FDA 503A/PCAC review; no TB-500 drug approval |
For the wider peptide evidence hierarchy, see our 7 Research Peptides Compared guide. In addition, compare MOTS-c with the KPV anti-inflammatory peptide guide, the GHK-Cu evidence guide, and our GLP-1 medicines comparison.
MOTS-c Peptide FAQ
Is MOTS-c legal in the UK?
MOTS-c is not a UK-licensed medicine. However, UK rules allow limited supply of some unlicensed medicines for a specific clinical need. Therefore, “unlicensed” is not a blanket answer to every possession or import question.
What is MOTS-c peptide studied for?
Researchers mainly study MOTS-c in relation to mitochondrial energy signals, AMPK, muscle biology, insulin-related metabolism and exercise. However, most treatment evidence still comes from lab and animal studies.
Does MOTS-c have human clinical trial data?
Human studies have measured the body’s own MOTS-c levels and exercise responses. By contrast, the FDA’s 2026 review found no clinical studies that gave MOTS-c-related drug substances to people.
Does exercise increase MOTS-c?
Yes, a 2021 human study found higher MOTS-c in skeletal muscle and circulation after exercise. In addition, other studies have measured mitochondrial peptides during exercise. However, these findings concern the body’s own MOTS-c and do not prove that added MOTS-c works as a treatment.
Does MOTS-c activate AMPK?
Lab and animal research links MOTS-c to higher AICAR and AMPK activity. However, researchers have not shown what that pathway means clinically for people who receive MOTS-c.
Is MOTS-c FDA-approved?
No. The FDA has not approved MOTS-c as a medicine. In addition, its 2026 staff review said the available criteria weighed against adding MOTS-c free base or MOTS-c acetate to the 503A Bulks List.
Bronnen
- Lee, C. et al. (2015), The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance, Cell Metabolism — original metabolic-homeostasis and AMPK-related study.
- Reynolds, J.C. et al. (2021), MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis, Nature Communications — includes human endogenous exercise-response data.
- Amerikaanse geneesmiddelenautoriteit FDA (2026) FDA Evaluation of MOTS-c-Related Bulk Drug Substances — official 503A briefing document for MOTS-c free base and MOTS-c acetate.
- Amerikaanse geneesmiddelenautoriteit FDA (2026) July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting — MOTS-c-related bulk substances were discussed on July 23.
- U.S. Food and Drug Administration, Bepaalde bulkstoffen voor magistrale bereidingen die aanzienlijke veiligheidsrisico’s kunnen opleveren — includes MOTS-c safety and human-exposure concerns.
- Medicines and Healthcare products Regulatory Agency (MHRA), Supply unlicensed medicinal products (specials) — UK framework for unlicensed medicines.
- Health Products Regulatory Authority (HPRA), Find a Medicine — Irish authorised-medicines search.
- European Union, Directive 2001/83/EC on medicinal products for human use, consolidated version applicable from 1 January 2025 — EU marketing-authorisation framework.